March 09, 2007

Market Study Highlights New Therapies for Schizophrenia

A new market study for the pharmaceuticals industry by NI Research reviews the status and prospects of new treatments that are in development for schizophrenia.

The review briefly notes the numerous 'me-too' drugs currently available and under development, including drugs from Vanda Pharmaceuticals, Organon, and Solvay.

The bulk of the review looks at the next generations of treatments for schizophrenia. This includes the most promising biochemical pathways for intervention: including glutamatergic, nicotinic, and 5HT-6 targets.

Some of the programs worth watching, the market report suggests, are those from Cortex partnered with Organon; Targacept ; Acadia Pharmaceuticals; Intra-Cellular Therapies; Memory Pharmaceuticals, and a pioneering effort to achieve regeneration in schizophrenia, in development by Allon Therapeutics.

Company Web Sites:
Cortex Pharmaceuticals
Acadia Pharmaceuticals
Intra-Cellular Therapies
Memory Pharmaceuticals,
Allon Therapeutics

Related Reading: New Schizophrenia Medications in Development (special report)


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required